Director/PDMR Shareholding

RNS Number : 7456F

Dechra Pharmaceuticals PLC

18 November 2020

 

18 November 2020

Dechra Pharmaceuticals PLC

Notification of Transactions by Persons Discharging Managerial Responsibilities

On 17 November 2020, Dechra Pharmaceuticals PLC (Dechra or the Company) was notified by a Director of the Company and Persons Discharging Managerial Responsibilities (PDMR) that he had completed the sale of part of his beneficial interest in Dechra.

Ian Page, Chief Executive Officer, has sold 300,000 ordinary shares in the Company as part of his long term personal financial planning.  Ian has also informed the Company that he has no plans to make further sales of his holding in the Company for a period of at least 12 months. Ian's continued participation in the Company LTIP further ensures his alignment and ongoing commitment to deliver on the Company's future performance targets.

Following this transaction, Ian continues to retain a beneficial holding of 338,919 which represents 0.314% of the current issued share capital in the Company.

The Notification of Dealing Form set out below is provided in accordance with Article 19.3 of MAR.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Sale of Shares
c)	Price(s) and volumes(s)	Price(s) £34.502	Volume(s) 300,000
d)	Aggregated information -Aggregate volume - Price - Total	300,000 £34.502 £10,350,661.20
e)	Date of the transaction	17 November 2020
f)	Place of the transaction	London Stock Exchange

Enquiries:
Dechra Pharmaceuticals PLC
Tony Rice, Chairman	Office:  [phone]
Ian Page, Chief Executive Officer	Office:  [phone]
Paul Sandland, Chief Financial Officer e-mail: [e-mail]	Office:  [phone]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail: [e-mail]	Office:  [phone] Mobile: [phone]

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com  

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

DSHKKFBNDBDDKDD